Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Core Viewpoint - Enliven Therapeutics, Inc. has successfully completed a public offering of approximately 9.92 million shares of common stock, raising about $230 million in gross proceeds before expenses [1]. Group 1: Offering Details - The public offering included the full exercise of underwriters' option to purchase an additional 1,526,250 shares at a price of $19.66 per share [1]. - In addition to common stock, pre-funded warrants to purchase 1,780,263 shares were offered at a price of $19.659 per warrant, reflecting the common stock price minus a nominal exercise price [1]. - The offering was managed by Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho, with LifeSci Capital serving as the lead manager [2]. Group 2: Regulatory Information - The offering was conducted under a Registration Statement on Form S-3, which was previously filed and declared effective by the SEC [3]. - A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are accessible through the SEC's website [3]. Group 3: Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics aimed at improving patient survival and overall well-being [5]. - The company employs a precision oncology approach to address unmet medical needs, leveraging insights into validated biological targets and innovative chemistry [5].